论文部分内容阅读
原发性再生障碍性贫血(简称再障)的病因未明,药物治疗对有些病例不能取得疗效,自1917年Eppingez氏首先应用脾切除治疗,此后国内外均有陆续采用,但对脾切除疗效的评价仍不一致。我们本着大协作的精神,综合分析脾切除治疗再障101例,报告如下: 一、病例的选择(一) 符合1964年全国血液学学术会议的诊断标准: 1.全血细胞减少(三系细胞减少的先后或程度可以不同)。2.骨髓检查显示至少一部分增生不良(包括增生减低或重度减低);如增生良好,须有巨核细胞的减少。3.能除外引起血液及骨髓改变的疾病。(二) 除个别病例外,脾切除前均经中西医治疗至少3个月以上无效者。西医如用丙酸睾
Etiology of primary aplastic anemia (referred to as aplastic anemia) etiology, drug treatment for some cases can not get curative effect, since 1917 Eppingez’s first application of splenectomy, since then have been adopted at home and abroad, but the effect of splenectomy Evaluation is still inconsistent. We in line with the spirit of large collaboration, a comprehensive analysis of splenectomy in the treatment of aplastic anemia in 101 cases, the report is as follows: First, the choice of cases (a) meet the 1964 National Hematology Conference diagnostic criteria: 1. Pancytopenia The level of reduction may be different). 2. Bone marrow examination showed that at least part of the poor proliferation (including reduced proliferation or severe reduction); if hyperplasia, there must be a reduction of megakaryocytes. 3. Can cause blood and bone marrow changes except the disease. (B) In addition to individual cases, before splenectomy were treated by Chinese and Western medicine at least 3 months invalid. Western medicine, such as testosterone propionate